Article Text

PDF
PWE-070 Intratumoural variability in prostaglandin E2 levels in human colorectal cancer liver metastases is associated with differences in NAD+ levels and expression of NAD+-dependent 15-prostaglandin dehydrogenase
  1. A L Young1,
  2. G Hawcroft1,
  3. R Chalmers1,
  4. G J Toogood2,
  5. M A Hull1
  1. 1Department of Molecular Gastroenterology, Leeds University, Leeds, UK
  2. 2Department of Hepatobiliary Surgery, St James's University Hospital, Leeds, UK

Abstract

Introduction Cyclooxygenase (COX)-2 (synthesis) and NAD+-dependent 15-prostaglandin (PG) dehydrogenase (15-PGDH; catabolism) are rate-limiting enzymes in control of tissue PGE2 levels. COX-2 and 15-PGDH function may be affected by the tumour micro-environment (eg, hypoxia) leading to changes in local PGE2 concentration and altered cancer cell behaviour. Epithelial-mesenchymal transition (EMT) is believed to be crucial for tumour cell invasion/metastasis. EMT is promoted by PGE2 in several cell types in vitro. We investigated the relationship between PGE2 levels, COX-2 and 15-PGDH expression, and NAD+ levels in human colorectal cancer liver metastases (CRCLM), and the role of hypoxia and PGE2 in EMT of CRC cells in vitro.

Methods PGE2 and NAD+ levels, and immunoreactive 15-PGDH and COX-2 protein content, were measured in paired central and peripheral tissue from 20 CRCLM. 15-PGDH activity was measured by a [3H]-PGE2 degradation assay in the presence or absence of exogenous NAD+ (1 μM). Parallel in vitro studies used a LIM1863 human CRC cell model of transforming growth factor (TGF) β-induced EMT and MCF-7 human breast cancer cells.

Results PGE2 levels were increased by a mean (95% CI) of 26% (1% to 52%) in the centre of CRCLM relative to peripheral tissue (mean 762 vs 604 pg/mg). Counter-intuitively, immunoreactive 15-PGDH protein levels were also increased (14% (3% to 27%)) in tumour centres, as was 15-PGDH activity in the presence of added NAD+ (16% (3% to 29%)). However, NAD+ levels were 59% (25% to 72%) lower in the centre of CRCLM than the periphery (mean 192 vs 546 pmol/mg) suggesting inefficient 15-PGDH-dependent catabolism may explain raised PGE2 levels. By contrast, there were no significant regional differences in immunoreactive COX-2 protein levels. In central areas of CRCLM, cancer cells exhibiting low E-cadherin expression had higher 15-PGDH expression than neighbouring E-cadherin-positive cells. Our CRCLM tissue observations were mirrored by LIM1863 cells undergoing EMT as hypoxic (1% O2) LIM1863 cells contained significantly less NAD+ and exhibited higher 15-PGDH protein levels than normoxic cells. 15-PGDH activity was significantly decreased in hypoxic MCF-7 cells compared with normoxic counterparts when NAD+ was present at a limiting concentration (no exogenous added). Furthermore, PGE2 (0.1–10 μM) promoted TGF-β-induced EMT in LIM 1863 cells in a concentration-dependent manner.

Conclusion Regional differences in PGE2 levels and 15-PGDH expression/activity are apparent in human CRCLM (possibly due to a hypoxic micro-environment). PGE2 promotes TGF-β-induced EMT in human CRC cells in vitro. Modulation of factors controlling PGE2 represents a novel therapeutic strategy against EMT in CRCLM.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.